Nektar Therapeutics (NASDAQ:NKTR) has received an average rating of “Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $24.57.
NKTR has been the topic of a number of research reports. BTIG Research dropped their price objective on shares of Nektar Therapeutics from $80.00 to $54.00 and set a “buy” rating on the stock in a report on Monday, November 8th. SVB Leerink dropped their price objective on shares of Nektar Therapeutics from $19.00 to $18.00 and set a “market perform” rating on the stock in a report on Monday, November 8th. Benchmark raised shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Monday, November 8th. Finally, Oppenheimer decreased their target price on shares of Nektar Therapeutics from $25.00 to $21.00 and set a “market perform” rating on the stock in a research note on Friday, November 5th.
In other news, CFO Gil M. Labrucherie sold 3,000 shares of Nektar Therapeutics stock in a transaction that occurred on Thursday, November 18th. The shares were sold at an average price of $12.69, for a total transaction of $38,070.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Gil M. Labrucherie sold 21,149 shares of Nektar Therapeutics stock in a transaction that occurred on Tuesday, November 16th. The shares were sold at an average price of $13.16, for a total transaction of $278,320.84. The disclosure for this sale can be found here. 2.91% of the stock is currently owned by company insiders.
There are 5.8 million people currently living with Alzheimer’s… Each patient is worth, on average, $27,672 a year.
This is why companies like…
